产品中心
productName |
Chemical Name |
Cas No. |
Final API | Indication |
Scale | Purity or Assay |
四氢异喹啉 | 1,2,3,4-Tetrahydroisoquinoline | 91-21-4 | MULTI | NA | Commercial | ≥98.0% |
N-乙酰基-4-哌啶酮 | N-Acetyl-4-piperidone | 32161-06-1 | MULTI | NA | Commercial | ≥98.0% |
2,6-二溴吡啶 | 2,6-Dibromopyridine | 626-05-1 | MULTI | NA | Commercial | ≥98.0% |
5,6,7,7a-四氢噻吩并[3,2-c]吡啶-2(4H)-酮盐酸盐 | 5,6,7,7a-Tetrahydro-thieno[3,2-c]pyridin-2(4H)-one Hydrochloride | 115473-15-9 | Prasugrel 普拉格雷 | NA | Commercial | 98.0%~102.0% |
5-苯氧基异苯并呋喃-1-(3H)-酮 | 5-phenoxyisobenzofuran-1(3H)-one | 57830-14-5 | MULTI | NA | Commercial | ≥99.0% |
(S)-2-(BOC-氨基)-3-[(S)-2-氧代-3-吡咯烷基]丙酸甲酯 | Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate | 328086-60-8 | PF-07321332帕罗韦德 | NA | Commercial | ≥99.0% |
2-甲氧基-4-溴苯酚 | 4-Bromo-2-methoxyphenol | 7368-78-7 | Aliskiren 阿利克伦 | NA | Commercial | ≥98.0% |
溴乙腈 | Bromoacetonitrile | 590-17-0 | PF-07321332帕罗韦德 | NA | Commercial | ≥99.0% |
(S)-4-苄基-2-唑烷酮 | (S)-4-Benzyl-2-oxazolidinone | 90719-32-7 | Aliskiren阿利克伦 | NA | Commercial | ≥99.0% |
2-乙基丁醇 | 2-Ethyl-1-butanol | 97-95-0 | Remdesivir瑞德西韦 | NA | Commercial | ≥99.5% |
(S)-3-氰基-5-甲基己酸乙酯 | (S)-3-Cyano-5-methyl-hexanoic acid ethyl ester | 181289-39-4 | Pregabalin普瑞巴林 | NA | Lab completed | ≥97.0% |
2-[[(3aR,4S,6R,6aS)-6-氨基四氢-2,2-二甲基-4H-环戊并-1,3-二恶茂-4-基]氧基]-乙醇 (2R,3R)-2,3-二羟基丁二酸盐 | 2-{[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy}ethanol | 376608-65-0 | Ticagrelor替格瑞洛 | NA | Commercial | ≥98.0% |
(1R,2S)-2-(3,4-二氟苯基)环丙胺 (R)-扁桃酸盐 | (1R,2R)-2-(3,4-difluorophenyl) cyclopropanamine(S)-(carboxylato(phenyl) methyl)holmium | 376608-71-8 | Ticagrelor替格瑞洛 | NA | Commerical | ≥98.0% |
4,5,6,7-四氢-5-甲基-噻唑并[5,4-C]吡啶-2-羧酸·盐酸盐 | 4,5,6,7-tetrahydro-5-Methy-Thiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride | 720720-96-7 | Edoxaban依度沙班 | NA | Commercial | ≥99.0% |
3-(S)-(+)-(1-氰基-1,1-二苯甲基)吡咯烷氢溴酸盐 | (3S)-a,a-Diphenyl-3-pyrrolidineacetonitrile HBr | 194602-27-2 | Darifenacin达非那新 | NA | Commercial | 95.0~103.0% |
4-氯吡咯并嘧啶 | 4-Chloropyrrolo[2,3-d]pyrimidine | 3680-69-1 | Tofacitinib托法替尼 & Ruxolitinib芦可替尼 & Baricitinib巴瑞替尼 & Abrocitinib阿布昔替尼 & Oclacitinib奥拉替尼 | NA | Commercial | ≥97.5% |
3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯胺 | 3-(4-Methyl-imidazol-1-yl)-5-trifluoro-methylphenylamine | 641571-11-1 | Nilotinib 尼罗替尼 | NA | Commercial | ≥98.0% |
苯基丁二酸 | DL-Phenylsuccinic acid | 635-51-8 | MULTI | NA | Commercial | ≥98.0% |
二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮 | 10H-Dibenzo[b,f][1,4]thiazepin-11-one | 3159-07-7 | Quetiapine喹硫平 | NA | Commercial | ≥99.0% |
3-萘基-2-((四氢呋喃基-2)-甲基)丙酸 | Naphthylmethyltetrahydrofurfurylpropanoic acid | 25379-26-4 | Nafronyl萘呋胺酯 | NA | Commercial | ≥99.0% |
1-萘甲基-(2-四氢呋喃甲基)丙二酸 | 2-Naphthalen-1-ylmethyl-2-(tetrahydro- furan-2-ylmethyl)-malonic acid | 115025-90-6 | Nafronyl萘呋胺酯 | NA | Commercial | ≥98.0% |
3-(甲氧基苯氧基)-1,2-环氧氯丙烷 | 1, 2-epoxy-3-(2-methoxyphenoxy)propane | 2210-74-4 | Ranolazine雷诺嗪 | NA | Commercial | ≥97.5% |
章胺盐酸盐 | Octopamine HCl | 770-05-8 | Ractopamine莱克多巴胺 | NA | Commercial | ≥98.0% |
覆盆子酮 | Raspberry ketone; 4-(4-hydroxyphenyl)-2-butanone | 5471-51-2 | Ractopamine莱克多巴胺 | NA | Commercial | ≥98.5% |
对甲基苯磺酰甲基异腈 | Tosylmethyl isocyanide | 36635-61-7 | MULTI | NA | Commercial | ≥98.0% |
2,8-双(三氟甲基)-4-羟基喹啉 | 2,8-bis(trifluoromethyl)quinolin-4-ol | 35853-41-9 | Mefloquine氟甲喹羟哌啶 | NA | Commercial | ≥97.0% |
N-叔丁基-十氢异喹啉-3(S)-甲酰胺 | (S)-N-t-butyl decahydro-3-iso-quinolinecarboxamide | 136465-81-1 | Nelfinavir甲磺酸萘非那韦 & Saquinavir沙奎那韦 | NA | Commercial | ≥98.0% |
5-氟胞嘧啶 | 5-Flucytosine | 2022-85-7 | Emtricitabine恩曲他滨 & Capecitabine卡培他滨 | NA | Commercial | ≥99.5% |
5-(4-氨基-5-氟-2-氧代-1(2H)-嘧啶)-1,3-氧硫杂环戊烷-2-甲酸-5-甲基-2-异丙基环己醇酯 | (2R,5S)-5-(4-Amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-[1,3]oxathiolane-2-carboxylic Acid,(2S)-Isopropyl-(5R)-methyl-(1R)-cyclohexyl Ester | 147126-75-8 | Emtricitabine恩曲他滨 | NA | Commercial | ≥99.5% |
(S)-2-苄基-N,N-二甲基氮杂环丙烷基-1-磺酰胺 | (S)-2-Benzyl-N,N-dimethylaziridine-1-sulfonamide | 902146-43-4 | Cobicistat考西司他 | NA | Commercial | ≥ 98.0% |
N-甲基-2-异丙基-4-噻唑甲胺二盐酸盐 | 1-(2-isopropylthiazol-4-yl)-N-methylmethanamine dihydrochloride | 1185167-55-8 | Cobicistat考西司他 | NA | Commercial | ≥ 98.5% |
N-[N-甲基-N-[(2-异丙基-4-噻唑基)甲基]氨基羰基]-L-缬氨酸 | (MTV-III) N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine | 154212-61-0 | Ritonavir利托那韦 | NA | Commercial | ≥98.0% |
N-[N-甲基-N-(((2-异丙基-4-噻唑基)甲基)氨基羰基]-L-缬氨酸锂盐 | N-[N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)aminocarbonyl]-L-valine lithium salt | 201409-23-6 | Ritonavir利托那韦 | NA | Commercial | ≥ 97.0% |
((5-噻唑基)甲基)-(4-硝基苯基)碳酸酯 | Carbonic acid 4-nitrophenyl 5-thiazolylmethyl ester | 144163-97-3 | Ritonavir利托那韦 | NA | Commercial | ≥98.0% |
3,5-二羟基戊苯 | 3,5-hydroxypentylbenzene | 500-66-3 | CBD大麻二酚 | NA | Commercial | ≥99.0% |
3,12-二氧代齐墩果-9(11)-烯-28-酸甲酯 | Olean-9(11)-en-28-oic acid, 3,12-dioxo-, methyl ester (9CI) | 218600-50-1 | Bardoxolone巴多索隆 | NA | Commercial | ≥98.0% |
1,3,5-三溴苯 | 1,3,5-Tribromobenzene | 626-39-1 | Buflomedil丁咯地尔 | NA | Commercial | ≥99.0% |
1,3,5-三甲氧基苯 | 1,3,5-Trimethoxybenzene | 621-23-8 | Buflomedil丁咯地尔 | NA | Commercial | ≥99.0% |
原甲酸三丙酯 | Tri-n-propyl orthoformate | 621-76-1 | MULTI | NA | Commercial | ≥98.0% |
4-(环丙基氧代甲基-a.a-二甲基苯基环己胺盐) | 4-(cyclopropyl-oxo-methyl-a.a-dimethylphenyl cyclohexylamine salt | 1690344-90-1 | Fexofenadine非索非那定 | NA | Commercial | ≥99.0% |
顺-4-苯硫基-L-脯氨酸 | cis-4-Phenylthio-L-proline | 81653-77-2 | Fosinopril福辛普利 | NA | Commercial | ≥98.0% |
沙格列汀 | Saxagliptin | 945667-22-1 | 361440-67-7 709031-45-8 361442-00-4 | CFDA USFDA | Ⅱ型糖尿病 | 98.0%~102.0% |
(4R)-1-甲基-4-(1-甲基乙烯)-2-环己烯-1-醇 | (4R)-1-methyl-4-prop-1-en-2-ylcyclohex-2-en-1-ol | 861892-40-2 | Cannabidiol大麻二酚 | NA | Commercial | ≥98.0% |
2-氯-1-(3,4-二氟苯基)乙酮 | 2-Chloro-1-(3,4-difluoro-phenyl)-ethanone | 51336-95-9 | Ticagrelor替卡格雷 | NA | Commercial | ≥98.0% |
枸橼酸托法替布 | Tofacitinib Citrate | 540737-29-9 | 3680-69-1 479633-63-1 | Lab completed | JAK通路抑制剂;类风湿性关节炎 | 98.0%~102.0% |
3-邻苯二甲酰亚胺丙醛 | 3-Phthalimidopropionaldehyde | 2436-29-5 | Atorvastatin阿托伐他汀 | NA | Commercial | ≥99.0% |
甲磺酸达比加群酯 | Dabigatran Etexilate Mesylate; Pradaxa | 872728-81-9 | 212322-56-0 | Lab completed | 抗凝血药物 | 98.0%~102.0% |
苄索氯铵 | Benzethonium chloride | 121-54-0 | 季铵盐类抗菌剂 | Commercial | ≥99.0% | |
恩曲他滨 | Emtricitabine | 143491-57-0 | 147126-75-8 2022-85-7 147126-62-3 | USFDA | HIV-1、乙肝 | ≥98.5% |
4-[2-(Boc-氨基)乙基]苯胺 | [2-(4-Aminoa-phenyl)-ethyl]-carbamic acid tert-butyl ester | 94838-59-2 | Mirabegron米拉贝隆 | NA | Commercial | ≥98.0% |